IRVING, Texas, May 15, 2026
Caris Life Sciences announced the publication of a new study in The Oncologist demonstrating the clinical value of its Caris Lookback Program, a dynamic precision oncology initiative designed to identify previously tested cancer patients who may become eligible for newly approved targeted therapies. The study showed that the program identified 13,293 patients across 10 tumor types who potentially qualified for new biomarker-driven treatment opportunities without requiring additional molecular testing.
The findings highlight a growing challenge in precision medicine: traditional molecular profiling reports are typically static and only reflect scientific evidence available at the time testing is performed. As new biomarker-targeted therapies continue to gain FDA approval, many patients with previously detected actionable mutations may miss emerging treatment opportunities. Caris developed the Lookback Program to continuously reanalyze historical molecular profiles against newly approved therapies, updated clinical guidelines, and evolving biomarker-drug associations.
Dynamic Molecular Profiling Identifies New Treatment Opportunities
According to the study, Caris Life Sciences reviewed 87 biomarker-directed FDA approvals between 2018 and 2025 using a structured clinical impact framework. Approximately one-third of those approvals met inclusion criteria for the Lookback Program based on clinical actionability and potential patient benefit.
Using a database containing more than 483,000 molecular profiles, the program identified thousands of patients who may now qualify for targeted therapies across multiple cancers, including non-small cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. Non-small cell lung cancer represented nearly 40% of all identified treatment opportunities, underscoring the increasing importance of precision biomarker testing in lung oncology.
The study also emphasized the critical role of multi-modal molecular profiling technologies, including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and Immunohistochemistry (IHC), in detecting actionable biomarkers linked to emerging therapies. Researchers noted that different biomarkers required different testing approaches, reinforcing the value of comprehensive genomic profiling platforms.
Advertisement
Caris Expands Long-Term Clinical Utility of Precision Medicine
A key differentiator of the Caris Lookback Program is its proactive physician engagement model. When new biomarker-linked therapies become clinically actionable, Caris coordinates outreach through its Medical Affairs and Molecular Science Liaison teams to notify treating oncologists about patients who may benefit from updated treatment options.
Company executives stated that the program demonstrates how a single comprehensive molecular test can continue generating clinical value years after the original biopsy, potentially reducing the need for repeat invasive procedures and additional testing. The initiative also aims to help clinicians keep pace with the rapidly expanding landscape of precision oncology therapies.
Caris highlighted that its MI Cancer Seek® platform remains the first and only simultaneous Whole Exome Sequencing and Whole Transcriptome Sequencing-based assay with FDA-approved companion diagnostic indications for molecular profiling in solid tumors.
As biomarker-driven oncology treatments continue expanding, dynamic reanalysis platforms like the Caris Lookback Program may play an increasingly important role in connecting patients to newly approved targeted therapies while improving long-term clinical decision-making in precision cancer care.
Source: Caris Life Sciences press release
